Volume 20, Number 11—November 2014
Letter
Antimicrobial Drug–Resistant Bacteria Isolated from Syrian War–Injured Patients, August 2011–March 2013
Table
Antimicrobial drug | No. MDR resistant isolates/no. total (%) |
|||
---|---|---|---|---|
Staphylococcus aureus, N = 19 | Pseudomonas aeruginosa, N = 10 | Escherichia coli, N = 8 | Acinetobacter baumannii, N = 6 | |
Amikacin | 1/ 11 (9) | 1/7 (14) | 6/6 (100) | |
Ampicillin | 5/5 (100) | |||
Amoxicillin/clavulanic acid | 6/6 (100) | |||
Cefotaxime | 6/8 (75) | |||
Ceftriaxone | 5/8 (62) | |||
Ceftazidime | 3/9 (33) | 5/8 (62) | 4/4 (100) | |
Cefepime | 5/8 (62) | 5/5 (100) | ||
Cefixime | 5/8 (62) | 5/5 (100) | ||
Ciprofloxacin | 7/17 (41) | 5/8 (62) | 2/7 (28) | 5/5 (100) |
Colistin | NA | NA | 0/5 | |
Trimethoprim/sulfamethoxazole | 3/14 (21) | 3/5 (60) | ||
Gentamicin | 10/18 (55) | 4/9 (44) | 4/8 (50) | 6/6 (100) |
Piperacillin/tazobactam | 2/9 (22) | 3/7 (42) | NA | |
Imipenem | 0/9 | 1/7 (14) | 4/5 (80) | |
Penicillin | 9/10 (90) | |||
Oxacillin | 7/17 (41) | |||
Clindamycin | 9/17 (52) | |||
Rifampin | 6/15 (40) | |||
Fusidic acid | 10/15 (66) |
*Blank cells indicate that testing was not done.
Page created: October 20, 2014
Page updated: October 20, 2014
Page reviewed: October 20, 2014
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.